BioSpace News Archive

STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).

BlueWind Medical, Ltd. is pleased to announce that the American Medical Association has issued a new Current Procedural Terminology code for the subfascial implantation of a tibial neuromodulation device for Overactive Bladder.

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted approval of its New Drug Application for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company’s proprietary nasal delivery device.

Kineta, Inc. announced today that Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference, a virtual event to be held on March 13-15, 2023.

Xeris Biopharma Holdings, Inc. today announced financial results for the fourth quarter and full-year 2022 and provided 2023 financial guidance.

Centogene N.V. today announced its conference schedule for March 2023.

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Merck is scheduled to participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on Wednesday, March 15, 2023, at 2:35 p.m. ET.

Matinas BioPharma Holdings, Inc. announces that it will report 2022 financial results after market close on Wednesday, March 15, 2023.

ONL Therapeutics, Inc. today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round.